Malignant Pleural Mesothelioma

Oncology
6
Pipeline Programs
5
Companies
6
Clinical Trials
1 recruiting
1
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
1
3
0
1
1
Early DiscoveryClinical DevelopmentMarket

On Market (1)

Approved therapies currently available

Novartis
ZORTRESSApproved
everolimus
Novartis
Kinase Inhibitor [EPC]oral2010

Competitive Landscape

5 companies ranked by most advanced pipeline stage

Novartis
NovartisBASEL, Switzerland
1 program
1
1
ZORTRESS(everolimus)Phase 21 trial
Active Trials
NCT01024946Completed11Est. Jul 2012
Ferring Pharmaceuticals
Ferring PharmaceuticalsArgentina - Buenos Aires
1 program
1
rAd-IFNPhase 31 trial
Active Trials
NCT03710876Active Not Recruiting53Est. Apr 2026
Sellas Life Sciences Group
1 program
1
Galinpepimut-S + Montanide + GM-CSFPhase 21 trial
Active Trials
NCT01265433Completed41Est. Jul 2017
Pfizer
PfizerNEW YORK, NY
1 program
1
PF-03446962Phase 22 trials
Active Trials
NCT01486368Completed17Est. Feb 2015
NCT01337050Completed36Est. Mar 2014
Roche
RocheSTAVANGER NORWAY, Norway
1 program
1
Dendritic cell vaccinationPhase 1/21 trial
Active Trials
NCT05765084Recruiting15Est. Oct 2026

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Ferring PharmaceuticalsrAd-IFN
PfizerPF-03446962
Sellas Life Sciences GroupGalinpepimut-S + Montanide + GM-CSF
Novartiseverolimus
RocheDendritic cell vaccination
PfizerPF-03446962

Clinical Trials (6)

Total enrollment: 173 patients across 6 trials

NCT03710876Ferring PharmaceuticalsrAd-IFN

Efficacy & Safety of rAd-IFN Administered With Celecoxib & Gemcitabine in Patients With Malignant Pleural Mesothelioma

Start: Jan 2019Est. completion: Apr 202653 patients
Phase 3Active Not Recruiting
NCT01486368PfizerPF-03446962

A Phase II Study of PF-03446962 in Patients With Advanced Malignant Pleural Mesothelioma

Start: Jun 2012Est. completion: Feb 201517 patients
Phase 2Completed
NCT01265433Sellas Life Sciences GroupGalinpepimut-S + Montanide + GM-CSF

Galinpepimut-S (WT-1 Analog Peptide) Vaccine in Malignant Pleural Mesothelioma After Combined Modality Therapy

Start: Dec 2010Est. completion: Jul 201741 patients
Phase 2Completed
NCT01024946Novartiseverolimus

Everolimus (RAD001) for the Treatment of Malignant Pleural Mesothelioma With Merlin/NF2 Loss as a Biomarker to Predict Sensitivity

Start: Dec 2009Est. completion: Jul 201211 patients
Phase 2Completed
NCT05765084RocheDendritic cell vaccination

Integration of the PD-L1 Inhibitor Atezolizumab and WT1/DC Vaccination Into Platinum/Pemetrexed-based First-line Treatment for Epithelioid Malignant Pleural Mesothelioma

Start: Feb 2023Est. completion: Oct 202615 patients
Phase 1/2Recruiting
NCT01337050PfizerPF-03446962

Asian Phase I Study Of PF-03446962

Start: Jul 2011Est. completion: Mar 201436 patients
Phase 1Completed

Related Jobs in Oncology

Senior Research Associate, Immuno-Oncology

SystImmune
9m ago
$60K - $85K/yr

Research Associate I/II, Immuno-Oncology

SystImmune
9m ago

Office Administrator

SystImmune
9m ago
$60K - $80K/yr

Scientist/Sr Scientist

TwoStep Therapeutics
San Carlos
19m ago

Working Student Office Management Support (m/f/d)

Mindpeak
Hamburg
23m ago

Senior Medical Project Manager (m/f/d)

Mindpeak
Hamburg
23m ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 late-stage (Phase 3) programs — potential near-term approvals
1 actively recruiting trials targeting 173 patients
5 companies competing in this space

Related Indications

Breast Cancer(530)Non-small Cell Lung Cancer(373)Prostate Cancer(371)Multiple Myeloma(244)Advanced Solid Tumors(221)Acute Myeloid Leukemia(204)Cancer(187)Neoplasms(173)Colorectal Cancer(166)Advanced Solid Tumor(165)